| Dhaval Sureja, MD | |
|
1901 Hamilton St, Suite 300, Allentown, PA 18104-6459 | |
| (610) 628-7920 | |
| (610) 821-2853 |
| Full Name | Dhaval Sureja |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 17 Years |
| Location | 1901 Hamilton St, Allentown, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033434436 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | MD454304 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Davita St. Luke's Bethlehem | Bethlehem, PA | Dialysis facility |
| St Luke's Hospital Bethlehem | Bethlehem, PA | Hospital |
| St Luke's Hospital - Anderson Campus | Easton, PA | Hospital |
| St Lukes Quakertown Hospital | Quakertown, PA | Hospital |
| St Luke's Hospital - Easton Campus | Easton, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St Luke's Physician Group Inc | 6709798333 | 1739 |
News Archive
There's a major roadblock to creating personalized cancer care. Doctors need a way to target treatments to patients most likely to benefit and avoid treating those who will not. Tumor biomarker tests can help do this.
A scientific "Renaissance man" whose work spans the fields of mathematics, linguistics, biotechnology and polymer physics, Erez Lieberman-Aiden, graduate student at the Harvard-MIT Division of Health Sciences and Technology, has been named the winner of the prestigious $30,000 Lemelson-MIT Student Prize. Lieberman-Aiden, one of four 2010 $30,000 Lemelson-MIT Collegiate Student Prize winners announced today, was selected for the breadth and depth of his innovations.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Regen BioPharma, Inc. announced today development of a novel means of delivering its patented (US Patent 8,263,571) gene silencing nucleic acid, RGBP-248, to liver tumors utilizing a clinically approved formulation as delivery system. The product in development overcomes previous hurdles with gene silencing therapeutics in which the gene silencing drug had to be delivered throughout the whole body.
AstraZeneca Pharmaceuticals LP and HealthCore, the health outcomes research subsidiary of WellPoint, today announced a collaborative agreement to conduct real-world studies designed to determine how to most effectively and economically treat disease.
› Verified 8 days ago
| Entity Name | St Lukes Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700984622 PECOS PAC ID: 6709798333 Enrollment ID: O20040226000062 |
News Archive
There's a major roadblock to creating personalized cancer care. Doctors need a way to target treatments to patients most likely to benefit and avoid treating those who will not. Tumor biomarker tests can help do this.
A scientific "Renaissance man" whose work spans the fields of mathematics, linguistics, biotechnology and polymer physics, Erez Lieberman-Aiden, graduate student at the Harvard-MIT Division of Health Sciences and Technology, has been named the winner of the prestigious $30,000 Lemelson-MIT Student Prize. Lieberman-Aiden, one of four 2010 $30,000 Lemelson-MIT Collegiate Student Prize winners announced today, was selected for the breadth and depth of his innovations.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Regen BioPharma, Inc. announced today development of a novel means of delivering its patented (US Patent 8,263,571) gene silencing nucleic acid, RGBP-248, to liver tumors utilizing a clinically approved formulation as delivery system. The product in development overcomes previous hurdles with gene silencing therapeutics in which the gene silencing drug had to be delivered throughout the whole body.
AstraZeneca Pharmaceuticals LP and HealthCore, the health outcomes research subsidiary of WellPoint, today announced a collaborative agreement to conduct real-world studies designed to determine how to most effectively and economically treat disease.
› Verified 8 days ago
| Entity Name | Gslpg, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366006702 PECOS PAC ID: 7810226875 Enrollment ID: O20190917001763 |
News Archive
There's a major roadblock to creating personalized cancer care. Doctors need a way to target treatments to patients most likely to benefit and avoid treating those who will not. Tumor biomarker tests can help do this.
A scientific "Renaissance man" whose work spans the fields of mathematics, linguistics, biotechnology and polymer physics, Erez Lieberman-Aiden, graduate student at the Harvard-MIT Division of Health Sciences and Technology, has been named the winner of the prestigious $30,000 Lemelson-MIT Student Prize. Lieberman-Aiden, one of four 2010 $30,000 Lemelson-MIT Collegiate Student Prize winners announced today, was selected for the breadth and depth of his innovations.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Regen BioPharma, Inc. announced today development of a novel means of delivering its patented (US Patent 8,263,571) gene silencing nucleic acid, RGBP-248, to liver tumors utilizing a clinically approved formulation as delivery system. The product in development overcomes previous hurdles with gene silencing therapeutics in which the gene silencing drug had to be delivered throughout the whole body.
AstraZeneca Pharmaceuticals LP and HealthCore, the health outcomes research subsidiary of WellPoint, today announced a collaborative agreement to conduct real-world studies designed to determine how to most effectively and economically treat disease.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dhaval Sureja, MD 1901 Hamilton St, Suite 300, Allentown, PA 18104-6459 Ph: (610) 628-7920 | Dhaval Sureja, MD 1901 Hamilton St, Suite 300, Allentown, PA 18104-6459 Ph: (610) 628-7920 |
News Archive
There's a major roadblock to creating personalized cancer care. Doctors need a way to target treatments to patients most likely to benefit and avoid treating those who will not. Tumor biomarker tests can help do this.
A scientific "Renaissance man" whose work spans the fields of mathematics, linguistics, biotechnology and polymer physics, Erez Lieberman-Aiden, graduate student at the Harvard-MIT Division of Health Sciences and Technology, has been named the winner of the prestigious $30,000 Lemelson-MIT Student Prize. Lieberman-Aiden, one of four 2010 $30,000 Lemelson-MIT Collegiate Student Prize winners announced today, was selected for the breadth and depth of his innovations.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Regen BioPharma, Inc. announced today development of a novel means of delivering its patented (US Patent 8,263,571) gene silencing nucleic acid, RGBP-248, to liver tumors utilizing a clinically approved formulation as delivery system. The product in development overcomes previous hurdles with gene silencing therapeutics in which the gene silencing drug had to be delivered throughout the whole body.
AstraZeneca Pharmaceuticals LP and HealthCore, the health outcomes research subsidiary of WellPoint, today announced a collaborative agreement to conduct real-world studies designed to determine how to most effectively and economically treat disease.
› Verified 8 days ago
Jessica Mary Boehmler, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1250 S Cedar Crest Blvd, Suite 205, Allentown, PA 18103 Phone: 610-439-8856 Fax: 610-439-8856 | |
Allison Jane Baragona, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1501 N Cedar Crest Blvd Ste 110, Allentown, PA 18104 Phone: 610-821-2828 Fax: 610-821-7915 | |
James A Burke, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1250 S Cedar Crest Blvd, Suite 300, Allentown, PA 18103 Phone: 610-402-3110 Fax: 610-402-3112 | |
Stephen R Shore, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1901 Hamilton St Ste 300, Allentown, PA 18104 Phone: 610-628-7900 Fax: 833-816-7513 | |
Tarika Sejal Chowdhary, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: 17th & Chew, Suite 101, Allentown, PA 18105 Phone: 610-969-4370 | |
Ashley Vojtek, DO Nephrology Medicare: Not Enrolled in Medicare Practice Location: 1200 S Cedar Crest Blvd, Allentown, PA 18103 Phone: 484-862-3200 | |
Dr. Ian William Klansek, MD Nephrology Medicare: Medicare Enrolled Practice Location: 2490 Schoenersville Rd, Allentown, PA 18109 Phone: 484-526-7262 |